Abbonarsi

Higher mortality in Extracorporeal Membrane Oxygenation patients during the COVID-19 pandemic compared with H1N1 influenza: implications for future pandemics - 22/10/25

Doi : 10.1016/j.rmed.2025.108311 
Harriet J. Caterson a, b, , Lauren Troy a, b, Moin Ahmed c, Paul Torzillo a, b, d, Rebecca Davis b, e, Stuart Duffin d, Paul Forrest b, f, Timothy Southwood d, Richard Totaro d, Helen Jo a, b, Edmund Lau a, b, Emma Gray a, b
a Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia 
b Central Clinical School, University of Sydney, NSW, Australia 
c Boden Initiative, Charles Perkins Centre, Faculty of Medicine and Health (Central Clinical School), The University of Sydney, NSW, Australia 
d Intensive Care Service, Royal Prince Alfred Hospital, Sydney, NSW, Australia 
e Infectious Diseases Department, Royal Prince Alfred Hospital, Sydney, NSW, Australia 
f Department of Anaesthetics, Royal Prince Alfred Hospital, Sydney, NSW, Australia 

Corresponding author. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, NSW, 2050, AustraliaDepartment of Respiratory and Sleep MedicineRoyal Prince Alfred HospitalNSW2050Australia

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

Veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) in management of refractory respiratory failure due to viral respiratory infections has increased with recent pandemics.

Aims

The aim was to compare clinical characteristics and outcomes of patients requiring ECMO support during an evolving pandemic with COVID-19, with patients during the H1N1-influenza pandemic and subsequent seasonal epidemics, where adjunct therapy and vaccination was available.

Methods

Medical records of inpatients at an ECMO referral centre diagnosed with COVID-19 between March 2020 and October 2022 and requiring ECMO support were analysed. The clinical characteristics and outcomes of these patients were compared to data from patients with H1N1 influenza requiring ECMO between July 2009 and August 2017, treated at the same centre. The primary outcome of in-hospital mortality was analysed with a multivariate logistic regression model; categorical and continuous variables were compared using Fisher's exact tests and two-sample T-tests, respectively.

Results

ECMO was used in 27 COVID-19 patients and 32 H1N1 influenza patients. Compared with H1N1 patients, COVID-19 patients were older (49.2 ± 9.0 vs 42.3 ± 11.1 years,p = 0.01), and more likely to have comorbidities (59 % vs 28 %,p = 0.02). Mortality was significantly higher for COVID-19 patients (52 % vs 6 %,p < 0.0001), odds ratio 16.8 (95 % CI: 1.27–221.39,p < 0.05). Days on ECMO were longer in the COVID-19 group (20 ± 13.3 vs 10 ± 5.6 days,p < 0.001). ECMO-related complication rates were similar between groups, apart from higher rates of secondary blood stream infections in COVID-19 patients (44 % vs 6 %,p < 0.001).

Conclusion

Outcomes in patients with COVID-19 requiring ECMO support were worse than those requiring similar support during H1N1 seasons.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Higher Mortality in COVID-19 ECMO Patients: COVID-19 patients on ECMO had a significantly higher in-hospital mortality rate (52 %) compared to H1N1 patients (6 %) (p < 0.0001).

Increased Complications in COVID-19: COVID-19 patients had a higher incidence of complications, including:

Secondary bloodstream infections (OR = 14.3; p = 0.003)
Neurological complications
Acute kidney injury requiring renal replacement therapy (RRT)

Longer ECMO Duration in COVID-19: COVID-19 patients required longer durations of ECMO support compared to H1N1 patients.

Age and Comorbidities Impact Mortality: Even after adjusting for age, BMI, gender, and ECMO duration, COVID-19 conferred a 16-fold higher risk of mortality compared to H1N1 (adjusted OR = 16.8).

Il testo completo di questo articolo è disponibile in PDF.

Keywords : COVID-19, Influenza, ECMO, Extracorporeal membrane oxygenation, ARDS, Respiratory failure, Hospital mortality, Viral pneumonitis


Mappa


 The authors received no financial support for the research, authorship and/or publication of this article. We declare no competing interests.


© 2025  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 248

Articolo 108311- novembre 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Non-pharmacological interventions for fatigue in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis
  • Xiaona Zhang, Jiali Xue, Yan Chang, Rui Zhang, Jie Zhao, Xindan Li, Hongyan Lu, Xirui Jiang, Fang Yu, Pengfei Yang
| Articolo seguente Articolo seguente
  • Telemonitoring in patients with COPD: A prospective study with results from the AIRE project
  • Francisco Marín Sánchez, Mercedes Sánchez Bommatty, Manuel Quero Haro, Francisco Ortega Ruiz, María del Mar Pérez Luque, Cristina Benito Bernáldez, Ana Muñoz Montiel, Víctor Fernández Gil, Francisco José Ávila Rodríguez, David Mateos Rueda, María Encarnación Fernández Martinez, Enrique Javier Vargas López, Ana Milagrosa Escribano dueñas, Fernando Ayuso Baptista

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.